Conference Coverage

What Is the Prevalence of Truly Benign MS?

The existence of benign MS is controversial, and patients with normal function in all domains are rare.


 

PARIS—Benign multiple sclerosis (MS) appears to be rare. Its estimated prevalence is less than 4%, according to a study described at the Seventh Joint ECTRIMS–ACTRIMS Meeting.

Emma Tallantyre, BMBS, PhD

The existence of benign MS has been proposed, but it remains controversial. Neurologists are uncertain about the frequency and pathologic explanation for a favorable outcome in MS. Identifying and studying individuals with benign MS would have “considerable implications for patient management and for our understanding of the biology of the disease,” said Emma Tallantyre, BMBS, PhD, Clinical Senior Lecturer in the Division of Psychological Medicine and Clinical Neurosciences at Cardiff University in the United Kingdom, and colleagues.

Most definitions of benign MS are focused on walking ability after 10 or 15 years, despite the far wider effects of MS on ability. Dr. Tallantyre and colleagues screened a prevalent population of more than 2,000 people with MS and found 275 individuals who had unlimited walking ability after 15 or more years from onset. The investigators undertook detailed assessments of 56 of the individuals within this group (ie, those recorded to have unlimited walking ability after the longest disease durations). Assessment incorporated scores of cognition, fatigue, mood, vision, bladder symptoms, and arm and leg function.

All patients were considered to have relapsing-remitting MS, but they showed a wide range of relapse frequency and severity. In a group of 32 patients who fulfilled a contemporary definition of benign MS based on the Expanded Disability Status Scale, the researchers considered less than 25% to be truly benign, which was defined as having normal function in all domains. Patient-reported scores of MS impact correlated strongly with the outcomes of clinical assessment, but patients’ own perceptions of their condition was more benign than clinicians’ perceptions.

MR imaging was used to explore the biology underlying benign MS using a global approach and a tract-based approach. The study provides early insights into the phenotypic and imaging characteristics of benign MS and could provide information about the biologic mechanisms of a favorable outcome in MS, said Dr. Tallantyre.

Recommended Reading

How Does Cognitive Demand Affect Mobility in MS?
ICYMI Multiple Sclerosis
Are Bladder Dysfunction and Falls Related in MS?
ICYMI Multiple Sclerosis
How Does Gender Influence Perceived Health in Older People With MS?
ICYMI Multiple Sclerosis
Can McArdle’s Sign Help Diagnose MS?
ICYMI Multiple Sclerosis
Can a Saliva Test Provide a New Biomarker for MS?
ICYMI Multiple Sclerosis
Serum Neurofilament Light Levels May Reflect the Efficacy of MS Treatments
ICYMI Multiple Sclerosis
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
ICYMI Multiple Sclerosis
DMTs Reduce the Risk of Conversion to Secondary Progressive MS
ICYMI Multiple Sclerosis
The Diagnostic Value of 2010 McDonald Criteria Versus 2016 MAGNIMS Guidelines for Special MS Populations
ICYMI Multiple Sclerosis
Which Factors Predict Conversion From CIS to MS?
ICYMI Multiple Sclerosis